EPRX is trading at $6.97 (5.8% up) in pre-market, extending strength seen during the recent biotech-led rally.
- The move appears tied to continued positive sentiment toward clinical-stage biotech names rather than a fresh company-specific catalyst.
- There are no new news or regulatory filings from Eupraxia Pharmaceuticals this morning.
- The price action represents follow-through from prior gains as momentum continues across the clinical-stage biotech sector.